These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. Roux S; Tschopp T; Baumgartner HR J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses. McCann ME; Watson TD; Boudinot FD; Moore JN Am J Vet Res; 1995 Aug; 56(8):1070-4. PubMed ID: 8533979 [TBL] [Abstract][Full Text] [Related]
29. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Harada N; Okajima K; Uchiba M Crit Care Med; 2006 Jul; 34(7):1883-91. PubMed ID: 16641616 [TBL] [Abstract][Full Text] [Related]
30. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174 [TBL] [Abstract][Full Text] [Related]
31. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
32. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951 [TBL] [Abstract][Full Text] [Related]
33. Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Galbusera M; Buelli S; Gastoldi S; Macconi D; Angioletti S; Testa C; Remuzzi G; Morigi M Xenotransplantation; 2005 Mar; 12(2):110-20. PubMed ID: 15693841 [TBL] [Abstract][Full Text] [Related]
34. Role of the liver and kidney in the desulphation of heparin in vivo. Wells XE; Dawes J Thromb Haemost; 1995 Aug; 74(2):667-72. PubMed ID: 8585004 [TBL] [Abstract][Full Text] [Related]
35. The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy. A randomized crossover study. Anderson DR; Ginsberg JS; Brill-Edwards P; Demers C; Burrows RF; Hirsh J Arch Intern Med; 1993 Apr; 153(7):841-4. PubMed ID: 8466376 [TBL] [Abstract][Full Text] [Related]
36. Disposition of a new heparan sulfate with fibrinolytic activity in the rat. Gervasi GB; Farina C; Bartoli C; Catalani R; Carpita G; Pistelli N Arzneimittelforschung; 1993 Apr; 43(4):445-9. PubMed ID: 8494575 [TBL] [Abstract][Full Text] [Related]
38. [The dynamics of the body distribution of heparin and its antagonist, the quaternary ammonium salt of conidine oligomer-25, when administered via the lungs]. Rumiantsev AG; Golovleva OA; Rozkin MIa; Kazarian VA; Efimov VS Farmakol Toksikol; 1991; 54(1):49-51. PubMed ID: 1860499 [TBL] [Abstract][Full Text] [Related]
39. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. Aghazadeh-Habashi A; Sattari S; Pasutto F; Jamali F J Pharm Pharm Sci; 2002; 5(2):181-4. PubMed ID: 12207871 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism. Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]